Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.
OBJECTIVE
This study evaluated the safety of coronary reactivity testing (CRT) in symptomatic women with evidence of myocardial ischemia and no obstructive coronary artery disease (CAD).


BACKGROUND
Microvascular coronary dysfunction (MCD) in women with no obstructive CAD portends an adverse prognosis of a 2.5% annual major adverse cardiovascular event (MACE) rate. The diagnosis of MCD is established by invasive CRT, yet the risk of CRT is unknown.


METHODS
The authors evaluated 293 symptomatic women with ischemia and no obstructive CAD, who underwent CRT at 3 experienced centers. Microvascular function was assessed using a Doppler wire and injections of adenosine, acetylcholine, and nitroglycerin into the left coronary artery. CRT-related serious adverse events (SAEs), adverse events (AEs), and follow-up MACE (death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization for heart failure) were recorded.


RESULTS
CRT-SAEs occurred in 2 women (0.7%) during the procedure: 1 had coronary artery dissection, and 1 developed MI associated with coronary spasm. CRT-AEs occurred in 2 women (0.7%) and included 1 transient air microembolism and 1 deep venous thrombosis. There was no CRT-related mortality. In the mean follow-up period of 5.4 years, the MACE rate was 8.2%, including 5 deaths (1.7%), 8 nonfatal MIs (2.7%), 8 nonfatal strokes (2.7%), and 11 hospitalizations for heart failure (3.8%).


CONCLUSIONS
In women undergoing CRT for suspected MCD, contemporary testing carries a relatively low risk compared with the MACE rate in these women. These results support the use of CRT by experienced operators for establishing definitive diagnosis and assessing prognosis in this at-risk population. (Women's Ischemia Syndrome Evaluation [WISE]; NCT00832702).
Division of Cardiology, Women's Heart Center, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Janet
J
Wei
Puja K
PK
Mehta
B Delia
BD
Johnson
Bruce
B
Samuels
Saibal
S
Kar
R David
RD
Anderson
Babak
B
Azarbal
John
J
Petersen
Barry
B
Sharaf
Eileen
E
Handberg
Chrisandra
C
Shufelt
Kamlesh
K
Kothawade
George
G
Sopko
Amir
A
Lerman
Leslee
L
Shaw
Sheryl F
SF
Kelsey
Carl J
CJ
Pepine
C Noel Bairey
CN
Merz
D000109:Acetylcholine; D000241:Adenosine; D000328:Adult; D001783:Blood Flow Velocity; D017023:Coronary Angiography / Q000009:adverse effects; D003326:Coronary Circulation; D003331:Coronary Vessels / Q000503:physiopathology*; D005260:Female; D006333:Heart Failure / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008833:Microcirculation; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology; D005996:Nitroglycerin; D011237:Predictive Value of Tests; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D014481:United States; D014665:Vasodilator Agents / Q000009:adverse effects
D014665:Vasodilator Agents; D005996:Nitroglycerin; D000241:Adenosine; D000109:Acetylcholine